Novartis (NVS) Partners With Alnylam for Liver-Targeted Therapies

Novartis (NVS) partners with Alnylam (ALNY) to collaborate on the discovery and the development of siRNA-based targeted therapy to restore functional liver cells.

Leave a comment

Your email address will not be published. Required fields are marked *